Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELVN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–2 Matrix Metrics)

ELVN Overall Winner 6-Pillar Tally: ELVN 3 – 2 VOR (1 Tie) Matrix Metrics: ELVN 4 – 2 VOR

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.62 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs VOR
ELVN NASDAQ Head-to-Head Winner
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.62
-2.42% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 59% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.2 · SMA20: $45.77 · SMA50: $46.19
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (ELVN 3 – 2 VOR)

Columns: Metric · ELVN · VOR
1. Valuation Multiples VOR
Forward P/E N/M N/M
Trailing P/E N/M 0.1x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ELVN
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $3.6B $1.2B
3. Profitability & Quality ELVN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -16.8% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$66M -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $150M Net Cash $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELVN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 61.7% (10th %ile) 127.0% (6th %ile)
Put/Call OI Skew 1.67x (Put-Skewed) 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (4) vs VOR (2)
Institutional Metric ELVN VOR Criterion Row Edge
Market Capitalization
Scale
$3.6B $1.2B Larger Scale ELVN
Trailing P/E Ratio
Valuation
N/M 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-16.8% -125.4% Higher ROE ELVN
52-Week Range Position
Momentum
69% ($15–$62) 64% ($6–$26) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.96β · 59% Vol 1.90β · 61% Vol Lower Realized Risk ELVN
Unified Institutional Score
Composite Signal
36.2 / 100 (SELL) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +22.39 pp
ELVN: +27.6% · VOR: +5.21%
3M Horizon VOR +2.22 pp
ELVN: -20.73% · VOR: -18.51%
6M Horizon VOR +14.09 pp
ELVN: +20.16% · VOR: +34.25%
1Y Horizon ELVN +40.37 pp
ELVN: +134.93% · VOR: +94.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs VOR. Trailing 12-month operating profitability (ELVN 0.0% vs VOR 0.0%) and valuation multiples (ELVN N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 61.7%
IV Percentile 10th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.62 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

ELVN leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

VOR screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 61.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 59% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.